Navigation Links
Uptake of Next-Generation Antifungals Has Intensified Competition in the Severe Fungal Infections Drug Market

However, Generic Erosion and a Dearth of Promising Emerging Therapies Will Result in Modest Annual Growth, According to a New Report from Decision Resources

WALTHAM, Mass., Nov. 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to their improvements in safety and efficacy, physicians are increasingly prescribing next-generation antifungals such as Pfizer's Vfend, Schering-Plough's Noxafil, Merck's Cancidas, Astellas' Mycamine and Pfizer's Eraxis. Following the recent launches of several next-generation azoles (such as Vfend and Noxafil) and echinocandins (such as Cancidas, Mycamine and Eraxis), the severe fungal infections market has become increasingly competitive.

The new Pharmacor report entitled Severe Fungal Infections finds that market competition will continue to intensify and the generic erosion of key agents and a dearth of promising emerging therapies will limit growth to a modest two percent annually from 2007 to 2017 in the severe fungal infections drug market. The report also finds that no new products other than Basilea's isavuconazole are expected to generate significant sales in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan through 2017.

"Interviewed physicians regard isavuconazole as a highly promising new antifungal, and we forecast the agent to be an important driver in the severe fungal infection market through 2017," said Jose Avalos, Ph.D., analyst at Decision Resources. "Isavuconazole provides a favorable spectrum of activity and safety and is likely to be available as both an oral and intravenous therapy. This agent will compete with other marketed drugs in its class and its sales will help offset the declines due to patent expiries of key brands over the next 10 years."

About Severe Fungal Infections

In 2007, severe fungal infections treatments generated more than $1 billion in sales in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The market for severe fungal infections is highly complex due to the heterogeneous patient populations, risk groups, and pathogens involved. Although five major antifungal products have launched in recent years, the current pipeline remains sparse despite significant remaining unmet need.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Decision Resources         Decision Resources, Inc.
    Christopher Comfort        Elizabeth Marshall
    781-296-2597               781-296-2563

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Uptake of Branded Agents Will Drive the Systemic Lupus Erythematosus Drug Market to Quadruple to $1.4 Billion in 2016
2. Varian and BrainLAB Announce Rapid Uptake of Powerful and Versatile Radiosurgery Platform
3. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
4. Analog Devices Healthcare Director Delivers Speech on Role of Analog Semiconductors in Next-Generation Portable Medical Equipment : ADI's Pat O'Doherty is a featured speaker at electronica 2008.
5. Satellite Healthcare Announces 2008 Norman S. Coplon Extramural Grants : Grants Foster Next-Generation Kidney Disease Researchers
6. Researchers find roadmap to next-generation cancer therapies
7. Fourth Annual Games for Health Conference Joins Health and Gaming Innovators to Discuss Next-Generation Game Technologies and Health Issues
8. VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System
9. iCAD Introduces Next-Generation TotalLook Film Digitizer
10. Sanofi Pasteur Enters Agreement With Crucell for Next-Generation Biologicals Against Rabies
11. Boston Scientific Announces CE Mark Approval for Next-Generation Cardiac Resynchronization Therapy Defibrillator
Post Your Comments:
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: